Insight

Aug 31, 2024, 17:06

Amir Safavi: How to improve the safety of SABR for ultra central thoracic tumors?

Amir Safavi, Radiation Oncology Fellow at Memorial Sloan Kettering Cancer Centre ,shared a post on X:

“Risk mitigation strategies for ultracentral lung tumors in IJROBP – The Red Journal:

Moderate plan dmax (eg 110-120%).
Limit OAR hotspots (esp Esophagus).
Avoid overly generous PTV.
Nodes treated cooler (eg 35/5) Accurate target and OAR contouring (use contrast).“Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultracentral Thoracic Tumors?Authors: Amir H. Safavi, David A. Palma and Meredith E. Giuliani

Source: Amir Safavi/X

Amir Safavi cancer David A. Palma IJROBP - The Red Journal LCSM Memorial Sloan Kettering Cancer Centre Meredith E. Giuliani OncoDaily Oncology SABR SBRT ultracentral lung

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers